Melanoma
Treatment Options
Adjuvant therapy
Metastatic
- extend overall survival
Combo BRAF/MEK inhibitor
Nivolumab + Ipilimumab
recommended first line for metastatic melanoma regardless of PDL1 expression
Pembrolizumab
Non-metastatic
- decrease recurrence time
Topical imiquimod or radiation if exclusion
Dabrafenib/trametinib (BRAF V600)
Ipilimumab
Surgery
Primary treatment
Drugs
PD-1 inhibitors
pembrolizumab
approved as single agent for resectable or metastatic melanoma
Nivolumab
approved for adjuvant treatment after complete resection
approved for single agent and in combo w/ ipilmumab for unresectable or metastatic melanoma
CTLA4 inhibitors
Ipilmumab
Tox
rash
diarrhea
liver tox
hypophysitis
manage diarrhea and livertox w/ high dose steroids
infliximab second line for diarrhea
mycophendlate second line for liver tox
infliximab contraindicated in liver disease
has the highest tox among checkpoint inhibitors
BRAF/MEK inhibitors
tox
skin oddities
pyrexia
diarrhea
eleved CK and LFTs
trametinib + cobimetinib
Dabrafenib + vemurafenib
also approved for adjuvant therapy for pt w/ mutation w/ lymph node involvement following complete resection
Approved for unresectable or metastatic melanoma w/ BRAF V600 mutations
IL-2
tox
capillary leak syndrome
constitutional symptoms
infections
N/V
chills
Steroids are CONTRAINDICATED due to risk of infections and GI side effects
administed in ICU
approved for metastatic melanoma
IFN alpha-2b
Avoid in
autoimmune
chronically immunosuppressed
liver disease
severe neuropsychiatric diseases
life-treat infection
tox
granulocytopenia
increased LFTs
flu symptoms
depression
anorexia
fatigue
approved for stage III high risk
Staging
Metastatic (Stage IV)
Systemic therapy for stage IV
Regional (Stage III)
Adjuvant therapy for stages IIB-IIIC
Localized (Stage I-II)
Surgery for stages 0-IIA